Open an account

RenovoRx

RNXT · NASDAQ

$1.20+$0.04 (+3.45%)TodayMarket closed ·
Prev close $1.16

About RNXT

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 17 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Employees
17
Headquarters
Mountain View, California
Listed
Aug 17, 2021
Sector
Health Care
Industry
Biotechnology
Website
renovorx.com

RNXT key statistics

Market cap
54.16M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
498.96K
Volume
264.59K
Open price
$1.16
High today
$1.24
Low today
$1.16
52 Week high
$2.59
52 Week low
$0.7006

RenovoRx (RNXT) at a glance

As of Oct 20, 2026, RenovoRx (RNXT) shares are priced at $1.20, giving the company a market cap of 54.16M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.16 and $1.24. The current price is 3.4% above the day's low and 3.2% below its high.

Volume so far is 264.59K shares, below the average of 498.96K shares a day.

Over the past year RenovoRx has ranged from $0.7006 to $2.59, and now sits 26% of the way up that range.

RenovoRx met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.074.

The average analyst price target is $7.27, 505.6% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $7.27
Low
$3.03
Now
$1.20
High
$15.23

RNXT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 10.7% on average.

  1. Q3 FY24: reported -$0.10 per share against an estimate of -$0.1224
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.1122
  3. Q1 FY25: reported -$0.08 per share against an estimate of -$0.0816
  4. Q2 FY25: reported -$0.08 per share against an estimate of -$0.0867
  5. Q3 FY25: reported -$0.08 per share against an estimate of -$0.0816
  6. Q4 FY25: reported -$0.08 per share against an estimate of -$0.0816
  7. Q1 FY26: reported -$0.09 per share against an estimate of -$0.0816
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.074

RNXT news

  • Press releaseGlobe Newswire

    RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

  • Vandana Singh

    EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

  • Press releaseGlobe Newswire

    RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

Similar companies

Companies in the same industry as RenovoRx

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.